Avadel Pharmaceuticals PLC Sponsored ADR Stock News

U.K. DISCLOSURE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1.      KEY INFORMATION (a) Full name of discloser: Avadel Pharmaceuticals plc (b) Owner or controller of interests and short posit...

– Generated LUMRYZ™ net product revenue of $77.5 million, a 55% increase compared to third quarter 2024 – – Approximately 3,400 patients on LUMRYZ as of September 30, 2025, a 48% increase compared to September 30, 2024 – – Announced global settlement of all litigation with  Jazz Pharmaceuticals, Inc.  (“Jazz”) – – Acquisition by Alkermes plc (“Alkermes”) expected to close in first quarter 2026 ...

The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revolution higher. Equities continue to hit all-time highs even the government shut down has nearly hit the one month mark and trade tensions remain between China and the U.S.

M&A activity has seen a notable pick-up in the biotech/biopharma industries over the past six weeks. This rise in deal volume has resulted in a nice rally in the sector, which has been a long-term laggard in a market driven by the AI narrative. In light of this improved investor enthusiasm, I have added to or established stakes in the three stocks highlighted in more detail in the paragraphs be...

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avadel Pharmaceuticals plc (NasdaqGM: AVDL) to Alkermes plc (NasdaqGS: ALKS). Under the terms of the proposed transaction, shareholders of Avadel will receive $18.50 per share, plus a non-transfera...

Shares of Alkermes and Avadel Pharmaceuticals diverged Wednesday after the former agreed to buy the latter for up to $2.1 billion.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avadel Pharmaceuticals plc (NASDAQ: AVDL) to Alkermes plc is fair to Avadel shareholders. Under the terms of the proposed transaction, Avadel shareholders will receive $18.50 per share, plus a non-transferable contingent value right entitling holders to a potential additional cash paym...

Alkermes said on Wednesday it will acquire Avadel Pharmaceuticals for up to $2.1 billion gaining access to the company's approved excessive daytime sleepiness drug.